Fibroinflammatory liver injuries as preneoplastic condition in cholangiopathies by Cannito, Stefania et al.
 International Journal of 
Molecular Sciences
Review
Fibroinflammatory Liver Injuries as Preneoplastic
Condition in Cholangiopathies
Stefania Cannito 1,† , Chiara Milani 2,† , Andrea Cappon 3 , Maurizio Parola 1,
Mario Strazzabosco 2,4,5 and Massimiliano Cadamuro 2,4,6,*
1 Department of Clinical and Biological Sciences, Unit of Experimental Medicine and Clinical Pathology,
University of Torino, Corso Raffaello 30, 10125 Torino, Italy; stefania.cannito@unito.it (S.C.);
maurizio.parola@unito.it (M.P.)
2 School of Medicine and Surgery, University of Milan-Bicocca, Via Cadore 48, 20900 Monza, Italy;
chiara.milani@unimib.it (C.M.); mario.strazzabosco@yale.edu (M.S.)
3 Department of Medicine (DIMED), Internal Medicine and Hepatology Unit, University of Padova,
Via Giustiniani 2, 35121 Padova, Italy; cappon.andrea@gmail.com
4 International Center for Digestive Health (ICDH), University of Milan-Bicocca, Via Cadore 48,
20900 Monza, Italy
5 Liver Center and Section of Digestive Diseases, Department of Internal Medicine, Section of Digestive
Diseases, Yale University School of Medicine, 333 Cedar Street, New Haven, CT 06520, USA
6 Department of Molecular Medicine (DMM), University of Padova, via Gabelli 63, 35121 Padova, Italy
* Correspondence: massimiliano.cadamuro@gmail.com or massimiliano.cadamuro@unimib.it or
massimiliano.cadamuro@unipd.it; Tel.: +39-02-6448-8089 or +39-049-827-6113
† These authors contributed equally to this work.
Received: 5 November 2018; Accepted: 1 December 2018; Published: 4 December 2018


Abstract: The cholangipathies are a class of liver diseases that specifically affects the biliary tree.
These pathologies may have different etiologies (genetic, autoimmune, viral, or toxic) but all of them
are characterized by a stark inflammatory infiltrate, increasing overtime, accompanied by an excess
of periportal fibrosis. The cellular types that mount the regenerative/reparative hepatic response to
the damage belong to different lineages, including cholagiocytes, mesenchymal and inflammatory
cells, which dynamically interact with each other, exchanging different signals acting in autocrine and
paracrine fashion. Those messengers may be proinflammatory cytokines and profibrotic chemokines
(IL-1, and 6; CXCL1, 10 and 12, or MCP-1), morphogens (Notch, Hedgehog, and WNT/β-catenin
signal pathways) and finally growth factors (VEGF, PDGF, and TGFβ, among others). In this review
we will focus on the main molecular mechanisms mediating the establishment of a fibroinflammatory
liver response that, if perpetuated, can lead not only to organ dysfunction but also to neoplastic
transformation. Primary Sclerosing Cholangitis and Congenital Hepatic Fibrosis/Caroli’s disease, two
chronic cholangiopathies, known to be prodrome of cholangiocarcinoma, for which several murine
models are also available, were also used to further dissect the mechanisms of fibroinflammation
leading to tumor development.
Keywords: cholangiocytes; neoplastic transformation; cholangiocarcinoma; primary sclerosing
cholangitis; Caroli’s disease
1. Introduction
Cholangiopathies are a large group of diseases of various etiology affecting the biliary epithelium,
with a chronic-progressive trend and often invalidating outcome; although rare in prevalence if
considered as a single entity, however, they are fairly common diseases, as a group. Cholangiopathies
are characterized by a high morbidity and mortality together with a significant financial burden to
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health care systems and families. Cholangiopathies represent a consistent proportion in the indication
for liver transplant (OLT) in the adult population, accounting for about the 16% in US in the period
between 1998 and 2014, and are the main indication for the pediatric population, responsible for
the 80% of the OLTx; in 2011 the costs for these interventions in the US reached $400 million [1,2].
In Italy, in 2008, diseases of the biliary tree were responsible for 10% of the hospitalizations for
gastroenterological diseases (33,657 patients), and the average hospital stay was 6.5 days for a total of
more than 220,000 days. The estimated annual social cost for the absence to the workplace account
to about 890,000€ for each patient (Italian Association for the Study of the Liver, White Book, 2011.
http://www.webaisf.org/pubblicazioni/documenti-finali-commissioni.aspx).
The etiology of cholangiopathies includes genetic and hereditary variants (Autosomal Dominant
Polycystic Kidney Disease (ADPKD), Autosomal Recessive Polycystic Kidney Disease (ARPKD),
Polycystic Liver Disease (PCLD), Chongenital Hepatic Fibrosis (CHF), Caroli’s disease (CD),
and Alagille Syndrome (AGS)), immune-mediated diseases (Primary Biliary Cholangitis (PBC), Primary
Sclerosing Colangitis (PSC), and Autoimmune Hepatitis (AIH)), pathologies associated to ischemia,
infections, or toxic agents, such as drugs, alcohol, and herbal remedies, tumors (cholangiocarcinoma),
and idiopathic diseases (Table 1) [3,4]. From a pathogenic point of view, cholangiopathies share
numerous fundamental lesions including different degrees of portal inflammation, cholestasis, and the
predisposition to develop biliary cirrhosis due to the progression of peribiliary fibrosis; moreover,
some of them, namely PSC and fibropolycystic liver diseases (ARPKD, CHF, and CD), could predispose
to cholangiocarcinoma (CCA) development [5,6].
Table 1. List of cholangiopathies of different etiology characterized by fibroinflammation.
Cholangiopathies Incidence Mutations Pathogenesis Clinical Features CCADevelopment
ADPKD 1:400–1000
85% to 90% PKD1
(polycystin 1), 10%
to 15% PKD2
(polycystin 2)
Ductal plate malformation,
biliary microhamartomas and
cysts, with scant fibrosis and
inflammation
Renal, hepatic and pancreatic
cysts, renal failure;
complications: Rupture,
infections and haemorrhages,
often associated with cerebral
aneurysm (20% of cases) and
cardiac valves abnormalities
Rare
ADPLD 1:100,000
PRKCSH
(hepatocystin) and
SEC63
(endoplasmic
reticulum
translocator)
Ductal plate malformation,
biliary microhamartomas and
cysts
Similar to ADPKD except for
renal implications Rare
Alagille Syndrome 1:30,000
50% to 60% JAG1
and rarely
NOTCH2
Progressive vanishing of
intrahepatic bile ducts
Biliary ductopenia, conjugated
hyperbilirubinemia, and liver
failure. Extrahepatic
manifestations may involve
heart, kidneys, skeleton and
face
Unknown
ARPKD 1:20,000–40,000
PKHD1
(fibrocystin/
polyductin)
Ductal plate malformation,
biliary microhamartomas, and
cysts; peribiliary fibrosis and
inflammation
Recurrent cholangitis, hepatic
cysts and microhamartomas,
and portal hypertension.
Renal multiple cysts, and
kidney failure
Rare
Autoimmune
Cholangitis
5% to 10% of
PBC patients
Chronic hepatic inflammation;
variant syndrome of
autoimmune hepatitis
Fatigue, pruritus, cholestasis,
bile duct injury followed by
ductopenia with little or no
portal inflammation
Unknown
Biliary Atresia
1:10,000–15,000
(50% of
pediatric liver
transplants)
80% to 90% perinatal form:
unknown etiology, probably
due to prenatal or perinatal
viral infection; bile duct injury,
inflammation, and obstructive
fibrosis.
10% to 20% prenatal (or early
severe) form: Likely genetic
Jaundice and alcoholic stools
due to fibro-obliterative
obstruction of the bile ducts.
Frequent progression in
secondary biliary cirrhosis
with splenomegaly and portal
hypertension
Unknown
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Cholangiopathies Incidence Mutations Pathogenesis Clinical Features CCADevelopment
Caroli’s disease 1:1,000,000
PKHD1
(fibrocystin/
polyductin)
Ductal plate malformation
leading to necroinflammation
of the biliary epithelia
Recurrent cholangitis, biliary
stones and cyst complications
6% to 30% of
cases
Cystic Fibrosis 1:3000
CFTR
(cAMP-dependent
Cl-channel)
Abnormal chloride
conductance on the apical
membrane of the epithelial
cells
Neonatal cholestasis, liver
steatosis, hepatomegaly, focal
biliary cirrhosis, and liver
cirrhosis with or without
portal hypertension.
Unknown
Primary Biliary
Cholangitis (PBC) 1:2500
Reduced expression of the
bicarbonate transporter
(SLC4A2) on the apical
cholangiocyte domain.
Non-suppurative
inflammation and destruction
of the interlobular bile ducts
Cholestasis, biliary cirrhosis,
serum antimitochondrial
antibodies, end-stage liver
disease
Unknown
Primary Sclerosing
Cholangitis (PSC) 0–16.2:100,000
Chronic inflammation in bile
ducts, immune-mediated
association with inflammatory
bowel disease
Chronic inflammation of
intrahepatic and extrahepatic
bile ducts, with obliterative
cholangitis and progression to
cirrhosis
10% of cases
The presence of an extensive portal inflammatory infiltrate coupled with intense peribiliary
fibrosis is one of the most significant histopathological features for the most of the cholagiopathies,
except for AGS, a genetic pathology due to mutation in Notch2 or Jagged1 genes and characterized by
the near absence of biliary tree and sinusoidal fibrosis with scant inflammation. In fibroinflammatory
diseases, bile ducts act not only as targets for the hepatic inflammatory response, for example in
immune-mediated cholangiopathies such as PBC and PSC, but also promote the recruitment and
activation of different cell types, among which are inflammatory cells and fibroblasts.
2. Cholangiocytes as Pacemakers of Fibrosis Deposition
Biliary epithelial cells (BECs), also termed cholangiocytes, can recruit and activate inflammatory
cells, thanks to their ability to secrete a range of pro-inflammatory cytokines and chemokines, which
intervene in both the Th1 (i.e., interleukin (IL)-2, and interferon (IFN)γ) [7] and Th2 (i.e., IL-4, -5,
and -6) [8] responses. Moreover, BECs have the ability to secrete growth factors, such as hepatocyte
growth factor (HGF), platelet derived growth factor (PDGF)-BB, and -DD, connective tissue growth
factor (CTGF), endothelin (ET)-1, vascular endothelial growth factor (VEGF), and transforming growth
factor (TGF)-β2, able to stimulate the activation of mesenchymal cells through paracrine signals and
therefore the production of extracellular matrix [4]. In fact, a histopathological finding characterizing
the majority of the cholangiopathies is the deposition of fibrotic tissue in the portal space, in close
proximity to reactive ductular biliary cells (RDCs), in accordance with the definition of ductular
reaction, namely the hyperplasia of biliary structures resulting from biliary damage, as the “pacemaker”
of liver fibrosis [9]. One of the most typical manifestations of cholangiopathies is the development of
cholestasis, due to the effect of different mechanisms including an altered ductal secretion induced
by the release of pro-inflammatory cytokines, as in immune-mediated cholangiopathies such as PSC
and PBC, or an altered expression or functioning of the membrane transporters of BECs, induced by
genetic defects, as occurs in cystic fibrosis, or finally the retention of hydrophobic bile acids that cause
apoptosis death of hepatocytes and the subsequent development of hepatocanalicular cholestasis.
3. Fibroinflammatory Response in Cholangiopathies
Fibrosis, as commonly accepted, is the consequence of excessive extracellular matrix (ECM)
deposition during scar tissue formation after chronic liver injury. This process is associated with
an increased and usually massive immune cells recruitment responsible for the modification of the
hepatic scaffold and an altered angiogenetic activity, ultimately resulting in organ failure. In healthy
liver, ECM normally present in the space of Disse, is composed by different Collagens (type I, III, IV,
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V, and VI), non-collagenous glycoproteins, such as laminin, and fibronectin, and proteoglycans [10].
In fibrotic liver, ECM deposition increases massively, up to tenfold, and also changes its normal
composition, increasing the presence of collage I and III [10]. Fibrosis is associated with the formation
of connective septa that interconnect the incoming vasculature (portal vein and hepatic artery branches)
and outgoing vessels (central veins) [11].
The scar tissue disrupts the integrity of the sinusoid plexus, composed by permeable vascular
spaces that are in direct contact with the hepatocytes, altering multiple metabolic functions of the
liver. The shunting of blood through major fibrotic vessels bypasses the low pressure hepatic sinusoids
causing portal hypertension, with increased risk of bleeding from esophageal or gastric varices,
accumulation of ascites in the peritoneal cavity and immunodeficiency. Although fibrosis is no longer
considered a static irreversible process in chronic diseases, the fibrotic process naturally leads to
cirrhosis and to liver tumor formation. The balance of matrix-degrading activity, determined in
turn by the balance of matrix metalloproteases (MMPs) and tissue inhibitors of MMPs (TIMPs), is
important in both progressive fibrosis and liver fibrosis regression. Exacerbation of fibrosis resulting
usually from chronic, non-resolving inflammation that triggers a wound-healing process that mitigates
inflammatory tissue destruction but also leads to scar tissue formation [12].
Once the equilibrium is perturbed and liver fibrosis progress, immune system cells and in
particular their mediators, play an active role in creating a fibrogenic milieu responsible for the
tumor initiation in liver tissue and in particular, cholangiopathies, due to the fibroinflammatory
microenvironment typical of these diseases are prone to develop neoplasias [13]. In this context,
cholangiocytes are continuously stimulated by chemokines and cytokines, growth factors, and other
soluble mediators that are responsible for damaging protoncogenes and tumor suppressor genes
involved in cell growth, apoptosis, invasiveness and angiogenesis.
In this review, we will elucidate the role of inflammation and of their mediators in the
establishment of a fibroinflammatory response leading to the worsening of the chronic cholangiopathies
and finally responsible for tumor initiation and development.
4. Cell Types Involved in Fibroinflammatory Response
4.1. Epithelial Cells
Hepatocytes and cholangiocytes, represent the two distinct liver epithelial cell types, which share
several epithelial hallmarks, but differ radically in how they organize their apical and basolateral
surface domains to fulfil different functions [14]. In cholangiopathies, BECs are the primary target of
the pathogenetic sequence, but also contribute to disease development and recovery after damage [1].
Cholangiocytes line the biliary tree, a complex network of conduits inside and outside the liver [3],
and regulate the fluidity and alkalinity of the bile secreted by the hepatocytes through a wide pool
of transmembrane channels, transporters, and exchangers [15]. In addition, they actively perceive
and respond to the inflammatory environment related to liver injury, as well as endogenous (bile
acids, lipids, nucleotides) and exogenous (microbial derived, xenobiotic, and drugs) molecules that
are able to modify cholangiocyte function and/or phenotype, affecting repair and remodeling of the
biliary epithelium [16]. To restore bile duct integrity after damage, cholangiocytes must proliferate
and then form branching tubular structures [17], a process originally termed “ductular reaction” [18].
These “reactive” cholangiocytes are characterized by motile properties and by the active production
of growth factors (e.g., VEGF, PDGF, and TGF-β) [9,19,20] cytokines/chemokines (e.g., IL-6, IL-8,
and tumor necrosis factor alpha (TNF-α)) [18,21,22], and morphogens (Hedgehog and Notch) [23],
establishing an extensive cross-talk with other cell types of mesenchymal origin [17,24]. Moreover,
liver “regeneration” can be sustained by the activation of the hepatic progenitor cells (HPCs), whose
involvement depends on the severity and nature of the injury and on the residual replicative ability of
hepatocytes and cholangiocytes [4]. HPCs are small cells, with an oval shape and scant cytoplasm,
and the ability to differentiate into the biliary or the hepatocyte lineage [25]. HPCs are thought to reside
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at the interface of the terminal ductules and the canals of Hering [26], or at the peribiliary extrahepatic
glands [27]. The differentiation of HPCs to the hepatocellular or biliary lineage depends on the type of
inflammatory reaction developing around the stem cell niche and is finely regulated by fundamental
morphogenetic signals such as Wnt/β-catenin, Hedgehog, and Notch [19,26,28,29]. While these
mechanisms are necessary during cholangiopathies to repair the biliary damage, it is worth mentioning
that they can also lead to undesired effects, such as the generation of an exaggerated neo-angiogenic
response with production of new fibro-vascular stroma and progressive liver fibrosis [30]. Increasing
evidence from murine models suggests that any type of liver epithelial cell, due to cellular plasticity,
can give rise to cholangiocarcinoma (CCA), an aggressive malignancy of the biliary epithelium,
characterized by late diagnosis and poor outcomes. In addition to the malignant transformation of
cholangiocytes and adult hepatocytes, CCA may develop from HPCs localized in the canal of Hering
or periductal glands stem niche [31] and HPC proliferation is directly related to cancer severity [32].
CCA deriving from HPCs presents phenotypic characteristics of both hepatocytes and cholangiocytes.
Examples of CCA subtypes with HPCs origin are cholangiocellular carcinoma (CLC) and combined
hepatocellular cholangiocarcinoma (CHC) [33–35]. Recently, Wu et al. [36] suggested that cell-cell and
cell-matrix interactions are essential for HPCs function and CCA progression. They demonstrated
that HPCs orchestrate the actions of myofibroblasts, immune cells, cytokines, matricellular proteins,
and inflammatory proteins in HPCs niche through the expression of specialized CCN (cysteine-rich
angiogenic protein 61 or CCN1; CTGF, or CCN2; nephroblastoma overexpressed or CCN3) proteins, in
order to promote HPCs differentiation and CCA development. This finding opens new opportunities
for future studies seeking to limit the uncontrolled activation of hepatic epithelial cells in order to
prevent both cholangiopathies and CCA.
4.2. Mesenchymal Cells
Myofibroblasts (MFs) are specialized α-smooth muscle actin (α-SMA)-positive cell types involved
in wound repair and liver fibrosis progression. In the liver there are multiple cell populations candidate
to be myofibroblast precursors, including hepatic stellate cells (HSCs), portal fibroblasts (PFs) and
fibrocytes. HSCs, constituting 5% to 15% of all hepatic cells, reside, in the normal liver, in the space
of Disse, which is the area between hepatocytes and sinusoidal endothelial cells [37]. In normal liver
HSCs, which are the major cellular store of Vitamin A and retinoid acid (RA) in the organism [38],
display a quiescent phenotype expressing several markers including glial fibrillary acidic protein
(GFAP), synaptophysin [39], desmin, and nerve growth factor (NGF) receptor p75 [40]. During
chronic liver injury, quiescent HSCs gradually lose vitamin A and RA and differentiate in activated
myofibroblast-like cells (HSC/MFs), acquiring proliferative, migratory, and contractile properties as
well as starting to produce collagen Type-I; HSC/MFs are responsible for the deposition of the majority
of ECM components [41–43] during fibrogenesis. Among HSC/MFs activation pathways, TGFβ and
PDGF are considered the major fibrogenic mediators [43]. Literature data indicate that HSC/MFs, at
least in murine models, are the predominant source of hepatic pro-fibrogenic MFs, regardless of the
aetiology [44,45], although other cells, including PFs and bone marrow-derived mesenchymal cells,
may represent additional sources of MFs. PFs are a population of resident fibroblasts, located in the
portal tract mesenchyme that surrounds bile ducts, and expressing a specific marker profile including
α-SMA, Collagen Type XV Alpha 1 (COL15A1), fibulin 2 (FBLN2), elastin (ELN), IL-6, cofilin 1
(CFL1), ecto-ATPase nucleoside triphosphate diphosphohydrolase-2 (NTPD2), and THY1 61 [43,46,47].
Moreover, similar to what was previously described for HSC/MFs, TGF-β represents the dominant
profibrogenic cytokine involved in PFs activation [43,48]. The contribution of PFs to sustain fibrosis is
considered particularly relevant in chronic cholangiopathies because PFs (i) act as “first responders”
in biliary fibrosis [49]; (ii) maintain the structure of the intrahepatic bile ducts [50]; (iii) interact
reciprocally with cholangiocytes, potentially influencing their state of activation and response to
injury [43]. Lastly, less than 5% of the hepatic MFs may derive from bone marrow-derived cells
including mesenchymal stem cells and fibrocytes. Fibrocytes, in particular, are mesenchymal cells
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arising from monocyte precursors that display both macrophages and fibroblasts features, co-express
haematopoietic and progenitor cell markers (CD45 and CD34, respectively), and are able to produce
ECM proteins. Fibrocytes have been reported to migrate into injured liver, possibly through signals
operating on C-C chemokine receptor type 1 and 2 (CCR1 and CCR2) [51–53].
4.3. Immune Cells
Liver resident macrophages (Kuppfer cells, KCs) are responsible for the surveillance on liver
homeostasis; typically, KCs can be found in both the centrilobular and periportal regions of the liver,
and their functions and structures differ depending on their location. KCs embryologically derive
from the yolk sac and, in normal conditions, represent up to 80% to 90% of all the macrophages of
the entire human body [54]. Following liver injury, KCs massively replicate and are able to recruit
monocytes from blood circulation, leading to an increase in local secretion of a bunch of peptides,
among which inflammatory mediators (TNF-α, IL-1β), that activate HSCs through the Nuclear Factor
Kappa-B (NF-κB) pathway, TGF-β and thrombospondin 1. HSCs activate MFs to secrete ECM proteins,
IL-4, IL-13, and PDGF, which in turn stimulate collagen synthesis by MFs [55]. On the other hands, KCs
are a reservoir of MMPs, in particular MMP12 and MMP13, produced in response to apoptotic cells
phagocytosis, MMP9 and TNF-related apoptosis-inducing ligand (TRAIL), involved in the promotion
of MFs apoptosis [55]. As previously discussed, macrophages could be considered a “double edge
sword”, since they can mediate fibrosis/fibrolitic processes, an effect that could be explained by the
heterogeneity of macrophages subset. In fact, the classical cataloguing M1, pro-inflammatory and
pro-fibrotic subset, and M2, restorative and anti-fibrogenic, is nowadays considered simplistic and far
from the real in vivo situation [56]. In murine models of chronic liver injury, KCs recruit from blood
numerous different monocytes, in particular Ly6Chi inflammatory cells, that once in the liver acquire
the typical CD11b+/F4/80+ Kuppfer phenotype. These cells are responsible for massive release of
pro-inflammatory cytokine, mainly IL-1β, TNF-α, IL-6, IL13, and TGF-β, which trigger HSCs and MFs
toward fibrosis activation [11]. Once the ECM is deposed and scar tissue formed, another subset of
immune cells, the LyC6lo macrophages, can be activated, and originate by the switch of LY6Chi due to
the phagocytosis of apoptotic cells. This mechanism is responsible for high expression and secretion
of MMPs and other anti-fibrogenic peptides, such as arginase 1 and chemokines receptor CX3CR1
in the local microenvironment [57]. In humans, similar heterogeneity is observed; in particular, in
cirrhotic livers human KCs are characterized by CD14lo and CD16−, while hepatic monocytes-derived
macrophages as CD14hi, CD16−, CD14+ and CD16+ [55]. Neutrophils are the first defense line for the
human body, as well as in the liver, but a clear role for this cell type in fibrotic/fibrolitic processes
is still debated. Natural killer (NK) cells have an active role in anti-fibrotic mechanisms, mainly
mediated by their expression of IFN-γ and of death receptors or ligands, such as Natural killer group
2-member D (NKG2D), TRAIL or Fas ligand (FasL), that modulate the activation of HSCs and MFs [55].
Moreover, NK cells are responsible for clearance of senescent HSCs, thus their deregulation may
directly have affected the fibrotic/fibrolitic balance [58]. Furthermore, fibrotic livers are infiltrated by
CD4+ T cells that actively participate to fibrosis progression. In particular, Th2 cells increase fibrosis
deposition by secreting IL-13 and leading to the hyper-expression of TGF-β1 by HSCs, ultimately
resulting in MMP9 expression and secretion, which, in turn, cleaves more pro-TGF, to further sustain
fibrogenesis [11]. On the other side, IFN-γ released by Th1 CD+ cells alters the MMPs/TIMPs balance
towards MMPs production, and activates fibrolisis. Another subset of T cells likely actively involved
in fibrosis progression are the Th17, that release IL-17, which activates its cognate receptor expressed
on HSCs surface, to stimulate the signal transducer and activator of transcription (STAT)3-dependent
synthesis of collagen I [13]. Tregs cells are putatively the counterpart of Th17 because this cell type
secretes IL-10 that, through the phosphorylation of STAT5, contributes to ameliorate fibrosis in rodent
models of BDL and parasitic infestation [10].
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5. Epithelial-Mesenchymal Cross-talk
In cholangiopathies, to restore the normal liver architecture, cell types involved in the
reparative/regenerative hepatic response, i.e., BECs (RDCs, and HPCs), cells of mesenchymal origin
(PFs, and HSCs), and inflammatory infiltrate (macrophages and neutrophils) interact each other
exchanging numerous peptides and sharing several ligands and receptors [17,59] (Figure 1). If this
finely tuned response is incorrect, this could lead to the establishment of a chronic cholangiopathy,
accompanied by the deposition of fibrosis, eventually leading to cirrhosis, and by a massive hepatic
inflammation. The interactions among these cell milieus are mediated by three different categories of
peptides that could be grouped as growth factors, proinflammatory and profibrotic cyto/chemokines,
and morphogens.
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Figure 1. Autocrine and paracrine signaling characterizing the cross-talk among the different cell
types involved in the development of cholangiopathies. Following a bile duct insult, cholangiocytes
start to secrete several mediators involved in the recruitment and activation of mesenchymal, as well
as inflammatory cells. Under the continuous stimulus induced by the chronic damage, fibroblasts
could accumulate in the portal tract and, together with hepatic stellate cells, could transdifferentiate to
myofibroblasts, directly responsible for the accumulation of periportal fibrosis. Similarly, damaged bile
ducts could recruit different types of inflammatory cells, among which T lymphocytes, neutrophils,
and macrophages (both M1 and M2), that further sustain the development of the disease.
Here, we briefly describe the functions of the main mediators involved in this cross-talk.
5.1. Growth Factors
The most studied and known growth factor involved in hepatic fibrogenesis is TGFβ. Once liver
insult is received, several cell types, among which cholangiocytes, MFs, HSCs, and KCs start to actively
secrete TGFβ, in particular the isoforms β1 and β2 [60]; this growth factor stimulates its receptors
TGFβRI and RII to activate a profibrogenic response through the activation of the Smad2/3-mediated
signaling [61]. Once phosphorylated, Smad2/3 create a multicomplex with Smad4 that migrates to
the nucleus to exert its transcriptional activity leading to the transcription of target genes, among
which collagens (I and IV), α-SMA, and MMPs [62]. Notably, TGFβ ligands are secreted mainly by
HSCs, endothelial cells (ECs) and KCs, that, by an autocrine-paracrine loop, are responsible for the
proliferation, activation and secretion of ECM proteins by HSCs. Despite the fact that cholangiocytes
are responsible, only in a minimal part, for the secretion of this growth factor, in cholangiopathies the
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presence of RDCs is fundamental for the activation of the latent TGFβ. In chronic cholangiopaties,
in fact, RDCs aberrantly express de novo αVβ6 integrin [63,64] that, together with its function as
a mediator of the cell-matrix interaction, is necessary for the modification of the so called “Small
Latent Complex”, composed by the latent form of TGFβ interacting with Latency Associated Peptide
(LAP) [65]. αVβ6 integrin cleaves the TGFβ/LAP complex and, once TGFβ is released as a monomer,
it can dimerize thus acquiring the ability to bind its specific receptor TGFβR [65]. VEGF and receptors
are a family of peptides composed of six ligands, VEGF-A to -E and by placental growth factor,
that bind their specific receptors VEGFR1, R2 and R3. Despite the initial belief that they exert their
proliferative effects on ECs only, mounting data demonstrate that VEGF ligands could be secreted
by several cell milieu and could activate cellular responses on cholangiocytes [66,67], HSCs [68],
and macrophages [69]. In ADPKD, the proliferation of liver cysts both in human and in animal
models of PC2 conditional KO mice, VEGF-A is hyper-secreted by BECs and stimulates liver cyst
enlargement in an autocrine fashion through a VEGFR2/(Mitogen-Activated Protein Kinase Kinase 1)
MEK/(Extracellular Signal-Regulated Kinase) ERK1/2/(Mammalian Target Of Rapamycin) mTor
axis [66,70,71]. Similarly, in the bile duct ligated (BDL) mouse model of chronic liver insult, VEGF
secreted by RDCs sustained the expansion of both RDC and HPC compartments [72]. VEGF secretion
could exert chemotactic and proliferative response in HSCs and also fuel their collagen secretion in the
liver microenvironment, thus contributing to the development of portal fibrosis and to the worsening
of the disease [73]. One of the most relevant family of growth factors involved in the establishment and
development of portal fibrosis is the Platelet derived growth factor (PDGF). PDGF family is composed
by five ligands (four homodimers PDGF-AA, -BB, -CC, and -DD, and one heterodimer PDGF-AB) and
by three cognate receptors, PDGFRα, PDGFRβ, and PDGFRαβ [74]. PDGF signaling supervises several
physiological mechanisms, both in normal and diseased conditions. In particular, the secretion of
PDGF-B by RDCs of BDL mice stimulates the proliferation and collagen secretion of HSCs; moreover,
PDGF-B induces the chemotactic recruitment of mesenchymal cells and the transformation and
activation of PFs to MFs, which are stimulated to proliferate and to actively produce ECM components
through the activation of the (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase) PI3K signaling [75].
Another PDGF ligand reaching even more importance is PDGF-D that in CCA, once secreted by
neoplastic cholangiocytes, is responsible for the recruitment of cancer associated fibroblasts (CAFs)
by the concomitant activation of (C-Jun N-Terminal Kinase) JNK signaling and Rho GTPases Rac1
and Cdc42 [76]. A profibrotic growth factor secreted in chronic liver diseases by a vast number of
cells, such as cholangiocytes, PFs, MFs, HSCs, and mast cells, is connective tissue growth factor (CTGF,
or CNN2). One of the factors involved in CTGF upregulation is TGFβ, that upregulates its expression
and secretion by HSCs mainly through (Activin Receptor-Like Kinase) ALK5/JAK1/Stat3 [77] and
ERK1/2 signaling [78]. Furthermore, CTGF has a potent chemotactic and trophic effect on HSCs and
induces their collagen secretion [79]. Chronic cholangiopathies characterized by an intense ductular
reaction and fibrosis deposition, such as biliary atresia and PSC, are characterized by a strong secretion
of CTGF [80,81] thus implying a potential pathogenic role of this growth factor in the worsening of
these diseases.
5.2. Morphogens
Different morphogenetic programs are deregulated in the onset and development of liver
diseases; here, we briefly cast an eye on the main signal pathways involved in the pathogenesis of
fibroinflammatory cholangiopathies. For instance, in normal conditions β-catenin acts as a structural
protein of the adherent junctions being a bridge between E-cadherin at the cell surface and α-catenin
and f-actin [82]. Usually β-catenin is maintained in an inert state into the cytoplasm by a so called
“destruction complex” composed by several proteins that stabilize it. In cholangiopathies, β-catenin
is phosphorylated and, if not ubiquitinated and destroyed, could reach the nucleus to activate the
WNT/β-catenin signaling. In the nucleus, β-catenin binds its specific transcription factor T-cell
factor/lymphoid enhancer factor (TCF/LEF). This mechanism is responsible for the transcription
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of several peptides, among which fibroinflammatory cyto and chemokines, such as chemokine
(C-X-C motif) ligands (CXCL)1, 10, and 12, and CTGF [64,83]; β-catenin nuclear entry represent
a fundamental step for the initiation of the proliferation and enlargement of RDC plexus [84] and is a
key regulator of the proliferation of HPC in adults suffering for different chronic liver diseases [85].
Furthermore, the activation of this signaling is involved in HSC-MF transdifferentiation and activation,
and in BDL mice, the inactivation of this signal pathway using an adenovirus carrying Dickkopf-1,
a WNT antagonist, is able to significantly reduce the extent of fibrosis [86]. Moreover, its aberrant
phosphorylation at the Ser675 of β-catenin in a mouse model of CHF/CD, act as protein stabilizer,
impeding its phosphorylation and degradation [87] thus stimulating the secretion of profibrotic and
proinflammatory mediators by cystic epithelia [64]. Another fundamental pathway involved in RDC
proliferation is Notch [88], a signal mechanism requiring the cell-cell contact and particularly important
in biliary differentiation and elongation along bile duct fetal development [28,89]; Notch (1 to 4) is
a family of receptors for different ligands (Jagged, and Delta) that, once docked, allow the cleavage
by γ-secretases of the notch internal cellular domain (NICD), that translocate to the nucleus to act as
the transcription factor binding the recombinant signal binding protein for immunoglobulin kappa J
(RBP-Jk) [17]. Notably, mutations of Notch2 or of its ligand Jagged1 are responsible for the development
of Alagille syndrome, a recessive genetic disease characterized by a lack of biliary structures that
fail to elongate from the hilum [89] and characterized by an accumulation of cells of intermediate
hepato-biliary morphology [90]. Recent papers outlined the importance also in the activation of
HPC niche in liver disease, and in the elongation of RDC as a fundamental inducer of the hepatic
reparative/regenerative response to liver injury [19,91]. Moreover, Notch signaling is involved in
inflammatory responses, acting concomitantly with TLR4, to stimulate the secretion of IFNγ, and of
chemokines, among which CXCL10 that is able to recruit infiltrating macrophages and to stimulate
their M1 polarization [92]. A third fundamental morphogenic signaling involved in the pathogenesis
of cholangiopathies is Hedgehog (Hh). Hh deregulation could act at a different level in hepatic
regenerative mechanisms responsible for fibrosis deposition and inflammation. During liver fetal
development it stimulates the proliferation of hepatoblasts [93] and maturation of fetal biliary epithelia
by controlling the expression of (Yes Associated Protein 1) YAP and Sox9, both transcription factors
necessary for biliary specification [94]. Notably, in liver diseases such as PBC [95], MFs, and RDCs
express high levels of Hh that could act in an autocrine/paracrine manner on surrounding cells and
MFs itself further stimulating the proliferation of BECs, through the upregulation of PDGF-B signaling
in an (Protein Kinase B Alpha) Akt-dependent fashion [96].
5.3. Proinflammatory Cyto and Chemokines
Another group of peptides deeply involved in the cross-talk among the different hepatic
cell types are the prionflammatory and profibrotic cytokines and chemokines. The diseased liver
microenvironment is usually full of such mediators that regulate the different pathways activated
during liver regeneration, among which Interleukins (IL-1, -6, -8, -13, and -33), monocyte chemotactic
protein (MCP)-1, IFNγ, and chemokine (C-X-C motif) ligands (CXCL1, 10, and 12). One of the
most important cytokines involved in liver regeneration is IL-6, the founder member of a large
family of peptides primarily involved in cell proliferation. It could be secreted by several cell types,
such as HSCs, KCs, and cholangiocytes, and, interacting with its receptor IL6R, it heterodimerizes
with the co-receptor gp130, leading to epithelial cells proliferation following phosphorylation of
Janus kinase (JAK) and STAT3 [97]. Other fundamental groups of ILs in the pathogenesis of chronic
cholangiopathies, in particular of biliary atresia, are IL-13 and IL-33. Following RRV infection, in fact,
RDCs start to secrete IL-33, which primes innate lymphoid cells type 2 (ILC2) to secrete a wide range
of ILs and growth factors, such as IL-13, Osteopontin, and TGFβ. IL-13, in turn, further stimulates
the proliferation of RDCs through a paracrine loop, sustaining the reactive ductular response typical
of this disease [98]. MCP-1 is a crucial chemokine responsible for the recruitment of monocytes at
the site of inflammation [99]. MCP-1 released by inflamed cholangiocytes interacts with its receptor
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CCR2 expressed by a subclass of circulating monocytes (CCR2+/CD14+/CD16−) that are actively
recruited and once transdifferentiated to macrophages are likely mainly responsible for the activation
of HSCs at the site of damage [100]. Moreover, MCP-1 is known to stimulate PFs proliferation,
transdifferentiation to MFs and the transcription of procollagen-1 precursors [101]. Fibroinflammatory
response in cholangiopathies is driven also by members of the CXCL family; the most studied is
CXCL12, also known as SDF-1, a chemokine with a prominent chemotactic on inflammatory cells, in
particular monocytes, lymphocytes, hematopoietic stem cells, and B cell precursors. PBC and PSC are
characterized by BECs hyperexpression of CXCL12, responsible for the recruitment of T cells carrying
its specific receptor C-X-C chemokine receptor type (CXCR) 4, the cognate receptor of CXCL12, and
sustaining the long-standing inflammatory state of these immune mediated diseases [102]; moreover,
HSCs are also responsive to CXCL12, that excites their proliferation and ability to secrete collagen [103].
Biliary cysts of CHF are characterized not only by the aberrant secretion of CXCL12, but also of other
cytokines, in particular CXCL1 (or KC), and CXCL10 (or IP-10) [64]. CXCL1 is a chemokine secreted
by numerous cell types, including epithelial cells, HSCs, macrophages, and neutrophils. It is mainly
involved in chemoattraction and proliferation of neutrophils [104], but several papers demonstrate
that its effect is not limited to this inflammatory cell type; CXCL1 could, in fact, stimulate proliferation
of HSCs in an autocrine loop, and inhibition of the PI3K/Akt pathway is able to slow cell proliferation
and, in vivo, to reduce development of fibrosis in a mouse model of carbon tetrachloride (CCl4)
intoxication [105]. Moreover, stimulation of TLR4 increases NF-kB-mediated secretion of CXCL1 in
a CFLD mouse model, likely responsible for the accumulation of neutrophils in CFTR-related liver
diseases [106]. CXCL10, through its receptor CXCR3, is involved in several pathophysiologic responses,
in primis recruitment of inflammatory cells, such as monocyte and macrophages, and NK and T cells,
and also in angiogenesis, cell adhesion and fibrogenesis. CXCL10 is upregulated in response not only
to IFNγ [107], but also by the activation of the β-catenin signaling [64]. Hypersecretion of CXCL10
in FPC-KO mice is responsible for the pericystic accumulation of macrophages and their M1-M2
transformation [64]. Moreover, the inhibition of its receptor with AMG-487, in vivo, leads to a reduced
fibrosis deposition accompanied by reduction in cystic area [83]. Furthermore, CXCL10 is considered
an independent biomarker of fibrotic development in HCV-transplanted patients [108] and correlates
with apoptosis in HCV patients [109]. It is worthy to highlight that secretion of inflammatory mediators
is involved not only in the recruitment and activation of inflammatory cells and fibroblasts, but that
their accumulation could lead to the persistent establishment of a chronic phlogistic response and in
the hyper activation of enzymes directly involved in the neoplastic degeneration of epithelial cells to
originate cholangiocarcinoma.
6. Mechanisms of Neoplastic Transformation
Cholangiocarcinoma (CCA) is a relatively rare and highly aggressive malignancy originating
from the neoplastic transformation of the intra or extrahepatic biliary tract epithelia. The incidence of
CCAs shows a marked variation worldwide, with intrahepatic CCAs being influenced by racial and
gender differences (CCA incidence is slightly higher in men) which is not significant in the case of
extrahepatic CCAs [110]. Although the aetiology of most CCAs remains undetermined [111] and risk
factors may vary geographically [110], several studies have identified a close relationship between
CCA development and chronic biliary tract infection and inflammation and, in particular, with the
pre-existence of chronic fibroinflammatory liver diseases, such as PSC and CD. Moreover, it is well
established that the oxidative stress and DNA lesions, as consequences of long-lasting inflammatory
processes, as in chronic cholangiopathies, play a key role in CCA development (Figure 2). In particular,
the persistent portal inflammation results in a sustained generation of endogenous compounds,
such as reactive oxygen species (ROS) and inducible nitroc oxide synthase (iNOS), that activate
several pro-inflammatory cytokines including TNF-α, IFNγ, TGFβ, and different ILs, thus causing
accumulation of nitric oxide (NO) in cholangiocytes, leading to nitrosative stress [112,113], finally
enhancing CCA progression. Oxidative and nitrosative stress can induce malignant transformation of
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epithelial cells directly, by inducing oxidative DNA lesions, characterized by multiple DNA single or
double-strand breaks and genetic instability, as also described for other cancers, or by inhibiting DNA
repair enzymes, as well as, indirectly, by affecting the cell proliferation/apoptosis ratio [113–116].
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Figure 2. Chronic inflammation is responsible for the neoplastic transformation of the biliary epithelial
cells. Alterations are due to the presence in the hepatic microenvironment of several molecules, such as
peroxinitrites and oxygen free radicals that could induce the accumulation of DNA damage. Nitric
oxide (NO) is able to stimulate cell proliferation and escape from apoptosis through the activation
of COX2 that stimulates the p38 MAPK/JNK axis to secrete PGE2, that further transactivates the
epidermal growth factor receptor (EGFR); this latter receptor also activates the PI3K/AKT pathway
responsible for the proliferation and resistance to apoptosis in cholangiocarcinoma (CCA).
In particular, nitric oxide (NO) and peroxynitrites are responsible for the formation of
8-oxo-7,8-dihydro-2′-deoxyguanosine (8-oxodG), and 8-Nitro guanine, two mutagenic compounds able
to inhibit DNA base repair and cause G→ T transversions. More relevantly, a study from Thanan and
colleagues [117] demonstrated that high levels of 8-oxodG was observed in the urine and leukocytes
of Opisthorchis Viverrini-infected patients also presenting CCA, thus suggesting the use of urinary
8-oxodG as biomarker to monitor not only infestation but also carcinogenesis. NO and peroxynitrites
may also favor the progressive accumulation of DNA damage in CCA by inhibiting the activity of DNA
damage reparative systems, as well as through the inactivation of 8-oxo-deoxiguanine DNA glycosylase
1 (hOGG1, the most important DNA repairing enzyme) [113,118]. Thanan and collaborators [111]
also hypothesized that CCA could derive from the neoplastic transformation and persistence of
liver stem/progenitor cells sti ulated by the condition of chronic and inflammatory liver injury. In
particular, they observed a significant correlation between increased levels of 8-oxodG and CD133-
and/or Oct3/4-positive cells compared to those in negative tissues [111]. Enhanced proliferative
signaling and evasion of apoptosis may constitute additional steps for the development of CCAs.
Concerning the effects of nitrosative and oxidative stress on the regulation of the balance between
epithelial cell proliferation and apoptosis, in conditions of persistent inflammation, accumulation of
NO and its derivatives are supposed to be responsible for the increased cell proliferation as well as for
the inhibition of pro-apoptotic mechanisms.
Furthermore, the iNOS-dependent COX-2 activation through the p38 MAPK/JNK axis, leads,
in CCA, to the generation of high amounts of prostaglandin E2 (PGE2), which in turn, by binding its
specific receptor EP1, can induce a tumorigenic effect by enhancing neoplastic cell proliferation and
invasiveness. In addition, PGE2 is able to transactivate the epidermal growth factor receptor (EGFR),
through a Src binding protein-mediated mechanism, resulting in the activation of PI3K/AKT signaling
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pathway, known to be responsible for proliferative and anti-apoptotic responses in CCA cells [119,120].
In particular, the activation of the PI3K/AKT pathway inhibits the Bad-Bclxl binding [121] and
the consequent mitochondrial Bax translocation, a critical step for activating the caspase cascade.
This anti-apoptotic effect induced by EGFR activation is counteracted by the treatment with celecoxib,
a selective COX-2 inhibitor [122]. On the other hand, NO can directly inhibit the activation of
caspases 3, 8, and 9, through nitrosilation of the cysteine residues present in the active site of
these caspases [123]. Neoplastic transformation could be also stimulated by xenobiotics that could
act as carcinogens, inducing directly inflammatory damage responsible for genetic alterations or
co-carcinogens, namely, substances, usually non-cancerogenetic, that act in concert with carcinogens
in promoting the onset of tumors. A known pro-neoplastic stimulus is the chronic administration
of thioacetamide (TAA), that induces liver injury followed by cirrhosis and cholangiocarcinoma
development after 30 weeks in rats [124]. Notably, the accumulation of bile acids following bile duct
ligation could burst the neoplastic development induced by TAA-treatment in rats by generating a more
sustained inflammatory environment and inducing RDCs proliferation respect to the TAA-treatment
only [125].
Recent data have also highlighted a critical role for Notch signaling in the formation of biliary
tract cancers [126] as well as an enhanced Notch expression in PSC patients and in those carrying
CCAs. In particular, NO-dependent activation of iNOS may also promote antiapoptotic mechanisms
by interfering with Notch signaling. Ishimura and colleagues [127] showed that in mouse CCA cell
lines, NO is able to induce the cleavage of the NICD1, which translocates into the nucleus to form a
transcriptional complex with recombination signal-binding protein 1 for J-kappa (RBPj), up-regulating
several target genes, among which hairy and enhancer of split-1 (Hes-1). This mechanism, mediated by
the activation of the JNK1/2 signaling, is believed to be responsible for increased cell survival and
reduced apoptosis of CCA cells [127].
7. Fibroinflammatory Cholangiopathies Heralding CCA
As previously described, some chronic fibroinflammatory biliary diseases could lead to the
development of CCA. The best known and studied nosologic conditions prodromal to neoplastic
transformation are PSC, and CD (Table 1); here, we briefly describe the main features of these two
diseases, the molecular mechanisms postulated to be involved in their tumoral degeneration, and the
main mouse models available for their study.
7.1. Primary Sclerosing Cholangitis (PSC)
PSC is a rare chronic cholangiopathy of autoimmune origin that affects about 250,000 individuals
in the EU and 200,000 people in the US. PSC is characterized by a strong peribiliary fibrosis and
inflammation, which can affect bile ducts of any size, from the smallest branches of the intrahepatic
ducts, to the extrahepatic major ducts. Its incidence in Western countries varies from 0.2% to 20% per
year, with higher percentage in the Scandinavian population, and a mild prevalence (60% to 65%) in
men; PSC often affects the young adult population (30–40 years), and is accompanied, in 70% of cases,
by chronic intestinal inflammatory diseases (IBD), in particular ulcerative colitis [128]. Histologically,
its pathognomonic lesion is the development of a thick concentric fibrotic hose around the biliary tree
leading to the development of cholangitis with fibro-obliterative evolution (onion-skin like fibrosis),
which determines the progressive vanishing of the bile ducts. The inflammatory infiltrate contains
mainly T lymphocytes and natural killer cells, which, through the secretion of IL-21, exert a potent
effect on fibroblasts proliferation and activation [129]. The prognosis of PSC is very variable, but not
infrequently the natural history of the disease is burdened by the high risk of developing malignant
tumors, not only at the biliary (cholangiocarcinoma), but also at the intestinal (colorectal carcinoma)
level. Unlike other cholangiopathies, such as PBC, the effectiveness of ursodeoxycholic acid (UDCA) is
not well recognized, and the only curative option remains the OLT, with a risk of recurrence in 30% of
cases [130].
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Different animal models for PSC are currently available for research purposes [131,132].
For example, Mdr2 knockout (Mdr2−/−) mice were obtained by genetically disrupting the Mdr2 (Abcb4)
gene, which is a mouse orthologue of human MDR3 (ABCB4), encoding for a canalicular flippase
expressed by hepatocytes, mediating the transport of biliary phospholipids into the outer leaflet of
the canalicular cell membrane, which enables their subsequent secretion into the bile. Inactivation
of the Mdr2 gene in mice produces periductular onion-skin type fibrotic lesions and pronounced
ductular reaction, liver fibrosis, early-onset severe portal hypertension, and increased transcripts of
Col1a1. In addition, Mdr2−/− mice present clinically relevant cirrhosis complications, such as primary
liver cancers [133]. Another genetically induced PSC-like model is the cystic fibrosis transmembrane
conductance regulator knockout (Cftr−/−) mouse, which harbors a mutation of exon 10 of the Cftr gene.
Cftr−/− mice develop focal cholangitis with thickened bile and bile duct proliferation, finally resulting
in biliary cirrhosis [134].
Regarding the association of PSC with the development of CCA, PSC is responsible for 10% of the
diagnosis for biliary neoplasia [135], in particular for young adults; the annual risk of developing this
neoplasia for patients suffering for PSC ranges from 0.6% to 1.5% and up to the 50% of the diagnoses
for PSC are followed by CCA development in the first 2.5 years [136–138]. Since PSC affects all the
districts of the intra and extrahepatic biliary network, CCA development could be associated with the
entire course of the biliary tree and often is proceeded by preneoplastic lesions such as intraepithelial
biliary or intraductal papillary neoplasias, but PSC patients usually develop mucinous or infiltrating
desmoplasic CCA [139,140]. The mechanisms leading to the neoplastic transformation of PSC to CCA
are actually unclear, but are associated with the persistence of a chronic inflammatory state of the
biliary tree. It was proposed that, in PSC, neoplastic transformation was associated to mutations of the
tumor suppressor p53, and of the oncogene KRAS [141,142]. Furthermore, recent studies outlined the
impact of NO production by iNOS as a stimulator of neoplastic transformation. NO in fact, not only
stimulates the expression of NOTCH, a signaling known to be involved in cholangiocarcinogenesis,
but can directly induce nicks in dsDNA [118], hamper the activity of enzymes involved in DNA
proofreading and repair [115], and impair the expression of oncosuppressors, such as p16 [143].
7.2. Caroli’s Disease (CD)
CD is a genetic cholangiopathy caused by mutations in polycystic kidney and hepatic
disease 1 (PKHD1), the gene coding for fibrocystin/polyductin (FPC), a large protein with a single
transmembrane domain expressed by cilia and centromers of cholangiocytes and renal epithelial
cells [144]. The FPC role remains unknown, but is thought to be involved in different cellular functions,
including regulation of cell proliferation, differentiation, secretion, tubulogenesis, and cell-matrix
interaction [145]. Due to FPC deficiency, CD is characterized by cystic dysgenesia of the intrahepatic
bile ducts, which preserve an immature phenotype (ductal plate malformations) and by portal
fibrosis, resulting in clinically relevant portal hypertension and related complications [3,17,146].
The mechanisms responsible for portal fibrosis in CD are still unclear, but recent studies have
shown that FPC-defective cells present several modifications in signaling mechanisms, including
Ca2+ homeostasis [147], 3′–5′-cyclic adenosine monophosphate (cAMP) [148] and mTOR [149]
pathways. In FPC-defective cholangiocytes, the increased cAMP/PKA signaling, which results in the
stimulation of cell proliferation and cyst expansion [148], is accompanied by PKA-dependent β-catenin
activation [150]. Indeed, PKA is able to phosphorylate β-catenin at Ser-552 and Ser-675, different from
those classically phosphorylated by Casein Kinase 1 Alpha 1 (CK1) and Glycogen Synthase Kinase
3 Beta (GSK3), preventing β-catenin degradation and resulting in its transcriptional activity [151].
Notably, recent findings suggest that the aberrant activation of β-catenin in FPC-defective epithelial
cells causes a chronic, low-grade inflammatory response [64] named “parainflammation”, a process
of adaptation to an unresolving cell dysfunction or noxious conditions [152]. When cell dysfunction
is persistent, the inflammatory response, unable to restore the normal tissue homeostasis, becomes
pathologic and can ultimately lead to scarring [152,153]. Thus, the development of fibrosis in CD
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depends on a complex interplay between epithelial and inflammatory cells, and exploring the factors
and the mechanisms that take part in this relationship may help in discovering new therapies against
cholangiopathies. This goal could be achieved by means of the Pkhd1del4/del4 mouse, a well-established
model of CD obtained with a targeting construct designed to inactivate Pkhd1 gene by disrupting exon
4 in mice with a C57BL6/129 mixed background. Pkhd1del4/del4 mice are characterized by intrahepatic
bile duct proliferation, progressive cyst formation, periportal fibrosis, and extrahepatic manifestations,
including pancreatic cysts, splenomegaly, and common bile duct dilation [154]. Another important
model is the Pkhd1del2/del2 mouse, obtained deleting Exon 2 of the Pkhd1 gene and replacing it with a
neomycin resistance cassette flanked by loxP sites, which could be subsequently removed by Cre-lox
recombinase. Phenotypically, the Pkhd1del2/del2 mouse is similar to the Pkhd1del4/del4 mouse, developing
altered bile ducts and enlarged portal triads, with portal fibrosis and cystogenesis [155]. Finally, the
polycystic kidney (PCK) rat has been suggested as a useful and promising animal model to study CD.
The PCK rat is a spontaneous mutant derived from a colony of Crj:CD rats, and was found to show
multiple segmental and saccular dilatations of the intrahepatic bile ducts, ductal plate malformation,
hepatic fibrosis and gross enlargement of kidney and liver [156].
CD is also considered a risk factor for CCA development, increasing the risk for
cholangiocarcinogensis by 30-fold [135]. In CD patients, and generally in patients with bile duct
cystic disorders, CCA is typically diagnosed at a mean age of 32 years, with lifetime incidence ranging
from 6% to 30% [157]. As for others risk factors, the malignant transformation of cholangiocyte in CD
conditions arises in a background of chronic inflammation, in which the high amount of cytokines
and factors secreted as a result of the aberrant activation of β-catenin in FPC-defective cholangiocytes,
triggers and maintains the process of cholangiocarcinogenesis [158]. Molecules participating in
this process promote neoplastic transformation by altering protooncogenes, DNA mismatch repair
genes or proteins, and tumor suppressor genes involved in cell growth, apoptosis, invasiveness, and
neoangiogenesis, inducing uncontrolled cell proliferation and invasion [159]. Therefore, reducing or
regulating the complex interplay between epithelial and inflammatory cells in CD patients could help
in monitoring not only the disease but also side effects, such as CCA development.
8. Conclusions
Most of the cholangiopathies share several pathological features, such as the peribiliary
accumulation of different cell types, among which fibroblasts and macrophages, whose intense
cross-talk is responsible for the initiation and persistence of the phlogistic processes and of
fibrosis deposition that accompanies these pathologies. Alongside these manifestations, cytokines,
chemokines, and growth factors released by the different cell populations, lead to the generation
and hyper-expression of reactive oxygen and nitrogen species that can cause damage to the genetic
heritage of the biliary cells that can predispose to the development of CCA. However, currently,
research is limited by the fact that, despite the existence of many well-established animal models
of cholangiopathies and of CCA, the investigators are still lacking animal models of neoplastic
transformation arising from cholangiopathies, useful for following the different steps of CCA
development, from the establishment of chronic inflammatory state, to the formation of dysplastic
nodules and then progressing to frank CCA. Thus, the above described rodent models of fibropolycystic
liver disease (Pkhd1del2/del2, Pkhd1del4/del4, and PCK,) or PSC (Mdr2−/−, and Cftr−/−), could be
successfully employed to evaluate if their mutations enable CCA carcinogenesis after toxic insults,
for example following chronic oral administration of TAA. Unravelling the molecular mechanisms
at the basis of fibroinflammatory responses in chronic cholangiopathies and the routes leading to
neoplastic transformation of the biliary epithelia, is a key step for the development of new strategies to
closely follow patients to prevent neoplasia development; furthermore, advances in the knowledge
of intimate molecular pathogenesis of cholangiopaties could lead to new therapeutic approaches,
actually lacking.
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